Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1873MR)

This product GTTS-WQ1873MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1873MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6127MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA COR-001
GTTS-WQ11610MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MGD-006
GTTS-WQ3275MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ11493MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ10146MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ13902MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-2176
GTTS-WQ11288MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ4998MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA C4G1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW